検索結果

Management Policy | About Senju | SENJU Pharmaceutical

re the action guidelines that Senju employees aim to follow. Company Vision（of our ideal future） To provide care that is effective for the five senses of people around the world A company that persist...

Clinical Trial Summaries | Research & Development | SENJU Pharmaceutica

t of Clinical Trial Summaries ※Listed in order of date of first publication Medical Condition Phase Project Code Country Recruitment Status Access to Trial ID Allergic Conjunctivitis 2 SJP-0049 Japan ...

Business Activities | About Senju | SENJU Pharmaceutical

ribute to the health of the eyes of people around the world, and a development policy that puts top priority on safety, we have always taken a pioneering path in ophthalmic pharmaceuticals. In the hop...

Business Activities | About Senju | SENJU Pharmaceutical

ribute to the health of the eyes of people around the world, and a development policy that puts top priority on safety, we have always taken a pioneering path in ophthalmic pharmaceuticals. In the hop...

病網膜症を対象とした RTH258D2301 試験（D2301 試験）（96 週）での眼内炎 症※3 の発現頻度は，本剤 6 mg 群で 5.5%（19/347 例），コントロール群［汎網膜光凝固 （PRP）］で 1.2%（4/342 例）であった。 一般に，眼内炎症は重症化すると失明に至る可能性があり，以上の結果を踏まえて製造 販売後の情報収集にて本リスクの特徴をより明らかにする必要があると考え...